REMEDIUMREMEDIUM1561-59362658-3534Joint-Stock Company Chicot178510.32687/1561-5936-2025-29-2-106-109Original ArticleAnalysis of the assortment of medicinal products containing glucocorticosteroids for the pharmacotherapy of atopic dermatitis in pediatricsSalnikovaAnna G.agsalnikova@yandex.ruDianovaDina G.dianovadina@rambler.ruPerm State Pharmaceutical Academy, Perm, Russia15122025210610917102025Copyright © 2025,2025In the last decade, there has been a steady upward trend in the incidence of atopic dermatitis, a genetically determined inflammatory skin disease, among the child population. The inclusion of topical glucocorticosteroids in pediatric practice is justified, since these drugs control the symptoms of dermatological disease, reduce the risk of severe course of the pathological process. In the course of the work, a list of glucocorticosteroids for topical use presented in pharmacies of the metropolis was studied. An assessment of the range of drugs in this group revealed that the proposed drugs have a variety of release forms and a wide price range. A study of the ratio of imported and domestic drugs revealed that the main country producing the analyzed drugs is Russia. However, in the list of these pharmacies at the time of the study, an insufficient range of concentrations (weak, moderate or strong activity) of topical glucocorticosteroids was noted, indicated in clinical guidelines for the treatment of atopic dermatitis in children. Thus, it has been established that it is necessary to expand the range of glucocorticosteroids for topical use for pharmacotherapy of atopic dermatitis in children of different age groups.pharmacytopical glucocorticosteroidspharmacotherapy of atopic dermatitispediatricsаптекатопические глюкокортикостероидыфармакотерапия атопического дерматитапедиатрияCaffarelli C., Giannetti А., Giannì G., Ricci G. Anti-inflammatory and biologic drugs for atopic dermatitis: a therapeutic approach in children and adolescents. Front. Med. 2023;10:1214963. DOI: 10.3389/fmed.2023.1214963Zaitseva N. V., Dolgikh O. V., Dianova D. G. Exposure to airborne nickel and phenol and features of the immune response mediated by E and G immunoglobulins. Health Risk Analysis. 2023;(2):160—168.Wang Q., Liu L., Gao S., Su S. Guidelines for the management of atopic dermatitis in children: a systematic review. Int. Arch. Allergy Immunol. 2023;184(2):132—141. DOI: 10.1159/000527007Клинические рекомендации. Атопический дерматит. 2023. URL: https://cr.minzdrav.gov.ru/view-cr/265_3Drucker A. M. Atopic dermatitis in 2023 and beyond. Br. J. Dermatology. 2023;188(6):691—692. DOI: 10.1093/bjd/ljad053Johnson H., Aquino M. R., Snyder A. et al. Prevalence of allergic contact dermatitis in children with and without atopic dermatitis: a multicenter retrospective case-control study. J. Am. Acad. Dermatol. 2023;89(5):1007—1014. DOI: 10.1016/j.jaad.2023.06.048Ilic I., Stojkovic A., Velickovic V. et al. Atopic dermatitis in children under 5: prevalence trends in Central, Eastern, and Western Europe. Children (Basel). 2023;10(8):1275. DOI: 10.3390/children10081275Wang Y., Shen C., Liu D. et al. Dupilumab improves clinical scores in pediatric patients aged 2 to < 18 years with uncontrolled atopic dermatitis: a single-center, real-world study. Dermatol. Ther. 2023;2023. DOI: 10.1155/2023/5626410Antonova A. A., Grishina A. M., Shabaev H. H. et al. Analysis of the incidence of diseases of the skin and subcutaneous tissue among university students. International Scientific Research Journal. 2023;6(132). DOI: 10.23670/IRJ.2023.132.129Krasheninnikova I. V., Dianova D. G. The importance of emollients in the pharmacotherapy of atopic dermatitis. Trends in the Development of Science and Education. 2021;(80—6):114—117.Dianova D. G., Salnikova A. G. Study of the pharmacy range of topical glucocorticosteroids used for the treatment of atopic dermatitis in children. Cardiovascular Therapy and Prevention. 2024;23(6S):92. DOI: 10.15829/1728-8800-2024-6S